Adbry may not be appropriate for everyone. It should not be used in patients with a known allergy to tralokinumab or any ingredients in the medication. Because Adbry modulates immune function, it is generally not recommended for patients with active serious infections. Your provider will review your health history before prescribing.

Live vaccines should not be given during Adbry treatment. If you have any upcoming vaccinations scheduled, inform your Honeydew provider before starting. Your provider will advise on timing and any vaccinations to complete before beginning treatment.

From an insurance perspective, most plans require step therapy before approving a biologic, meaning documentation that topical treatments were tried first. Your Honeydew provider will assess your treatment history and determine whether Adbry is the appropriate next step, or whether a different approach — such as a different biologic or a JAK inhibitor like Rinvoq — may be a better fit for your situation.

Adbry (tralokinumab), Ebglyss (lebrikizumab), and Dupixent (dupilumab) are all biologic injections approved for moderate to severe atopic dermatitis in patients ages 12 and older. All three target the IL-13 or IL-4/IL-13 inflammatory pathway, but they differ in mechanism, dosing schedule, and insurance coverage.

Adbry vs. Ebglyss: Both are IL-13 inhibitors, but they bind to IL-13 differently. Ebglyss prevents IL-13 from binding to receptor complexes, while Adbry neutralizes IL-13 directly. Clinically, both have demonstrated strong eczema clearance rates. Dosing is comparable — every two weeks after starter doses for both, with the possibility of every-four-weeks maintenance dosing for Adbry in eligible patients. Insurance formulary placement varies significantly between the two, and Honeydew will help identify which is better covered under your specific plan.

Choosing between them: There is currently no published head-to-head trial between Adbry and Ebglyss. Your Honeydew dermatologist will consider your treatment history, insurance coverage, and skin response when recommending between these options.

Yes. Adbry can be used with or without topical corticosteroids, and many patients use both during treatment, particularly during the initial weeks before Adbry reaches its full effect. Topical calcineurin inhibitors (like tacrolimus) may also be used alongside Adbry, though providers typically reserve these for specific problem areas such as the face, neck, and skin folds.

Combining Adbry with topical treatments is common and clinically supported. In clinical trials (ECZTRA 3), Adbry plus topical corticosteroids was studied specifically and showed strong outcomes in adults with moderate to severe atopic dermatitis.

Your Honeydew dermatologist will advise on which combination approach is right for your skin and how to transition your topical treatments as Adbry takes effect.

Biologics are a class of prescription medications derived from living cells that target specific proteins in the immune system rather than broadly suppressing immune function the way older systemic treatments like cyclosporine or oral steroids do. For atopic dermatitis (eczema), biologics like Adbry work by blocking specific inflammatory proteins (in Adbry's case, IL-13) that trigger the itching, redness, and skin barrier breakdown characteristic of eczema flares.

Your dermatologist may recommend a biologic like Adbry if topical treatments — including prescription-strength corticosteroids and calcineurin inhibitors — have not provided adequate control of your eczema, or if your atopic dermatitis is moderate to severe and significantly affecting your quality of life. Biologics represent the most targeted and generally well-tolerated systemic treatment option currently available for difficult-to-control eczema.

Honeydew's board-certified dermatologists are experienced in prescribing and managing biologic therapy for eczema entirely online, including all monitoring, insurance coordination, and specialty pharmacy management.

Yes. Adbry is FDA-approved for patients ages 12 and older with moderate to severe atopic dermatitis whose eczema is not adequately controlled with topical prescription treatments. This makes it one of only a few biologic options available for adolescents with difficult-to-control eczema.

For patients ages 12 to 17, the dosing is slightly different from adults: the initial dose is 300 mg, followed by 150 mg every two weeks. As with adults, a parent or guardian must be part of the initial consultation for patients under 18, and Honeydew can accommodate this through our virtual care process.

If your teenager has been struggling with moderate to severe eczema that hasn't responded to topical treatments, Adbry may be worth discussing with a Honeydew dermatologist.

Conjunctivitis (pink eye) is the most commonly reported eye-related side effect of Adbry, and it's worth knowing about before you start treatment. In clinical trials, conjunctivitis occurred in a minority of patients and was classified as mild to moderate in the majority of cases. Most patients who experienced conjunctivitis continued treatment and managed it with lubricating or corticosteroid eye drops under their provider's guidance.

If you develop new redness, irritation, discharge, or discomfort in your eyes while on Adbry, let your Honeydew care team know promptly. In most cases these symptoms are manageable without stopping treatment, but your provider will assess whether ophthalmologic care is needed.

One practical note: if you've previously been on Dupixent and stopped due to eye-related side effects, Adbry may be worth discussing with your provider as an alternative — the two biologics affect the eye differently, and some patients who couldn't tolerate conjunctivitis on Dupixent have done well on Adbry.

Adbry is given as a subcutaneous injection, a small shot administered just under the skin, typically in the abdomen or thigh. It comes as a prefilled syringe or autoinjector pen designed for self-administration at home. Adults typically use the autoinjector pen; your provider or specialty pharmacy will walk you through the injection process before your first dose.

The dosing schedule works as follows: you begin with a loading dose of 600 mg (four 150 mg injections given at the same time), then continue with 300 mg (two injections) every two weeks. Adults who weigh less than 220 lbs and achieve clear or nearly clear skin after 16 weeks of treatment may be eligible to reduce to 300 mg every four weeks — roughly once a month — which significantly reduces injection frequency.

If self-injection isn't comfortable for you, your provider can arrange for your doses to be administered at a specialty pharmacy or healthcare facility.

Yes, tralokinumab is the generic (scientific) name for Adbry. You may see "tralokinumab-ldrm" on your insurance paperwork, prescription label, or medical records. It is the same medication. Adbry is the brand name manufactured by LEO Pharma.

Tralokinumab is a monoclonal antibody that works by selectively binding to and blocking IL-13, an immune protein that plays a central role in driving the inflammation, itching, and skin barrier disruption associated with atopic dermatitis. There are currently no FDA-approved biosimilar (generic equivalent) versions of tralokinumab available in the United States.

Most patients begin to notice improvement in itching and skin inflammation within the first 1 to 2 weeks of starting Adbry. More significant eczema clearance — including reduction of plaques, redness, and widespread flares — typically becomes visible by weeks 8 to 16. In clinical trials, approximately 65 to 75% of patients achieved clear or nearly clear skin at 16 weeks (about 4 months) of consistent treatment.

Results continue to improve with ongoing use. Long-term clinical data shows sustained eczema control in patients who remain on treatment, with many maintaining clear or nearly clear skin beyond the first year.

If you haven't seen meaningful improvement after 16 weeks, contact your Honeydew care team. Your provider may adjust your treatment plan, discuss combination options with topical corticosteroids, or explore whether a different biologic is a better fit.

Yes, Honeydew's board-certified dermatologists prescribe and manage Adbry entirely online. No in-person office visit is required. You complete a medical questionnaire and share your skin history and photos, and a licensed dermatology provider reviews your case. If a video consult is needed, it can typically be scheduled within 48 hours.

From there, your dermatologist confirms your eligibility, manages prior authorization with your insurance, and coordinates with a specialty pharmacy for delivery. Adbry requires ongoing monitoring and check-ins — all of which Honeydew manages virtually, without you needing to visit a clinic.

Yes, most insurance plans require prior authorization before covering Adbry, and many also require step therapy, meaning you may need documentation showing that topical prescription treatments were tried first before a biologic is approved. The prior authorization process typically takes 2 to 4 weeks once submitted.

This is often the most stressful part of starting a specialty biologic and it's something Honeydew handles entirely on your behalf. Your provider prepares and submits prior authorization documentation, follows up with your insurer, and coordinates with the specialty pharmacy to minimize delays. If your authorization is initially denied, we guide you through the appeals process and can help you access bridge programs in the meantime so you're not waiting without treatment.

Getting Adbry prescribed online through Honeydew doesn't mean navigating insurance paperwork alone — we manage the access process from start to finish.

Adbry (tralokinumab) and Dupixent (dupilumab) are both FDA-approved biologic injections for moderate to severe atopic dermatitis, and both are prescribed by Honeydew's dermatologists. They work through similar but distinct mechanisms — and the differences between them matter for certain patients.

How they work: Dupixent blocks both IL-4 and IL-13, two proteins that drive eczema inflammation. Adbry specifically targets IL-13 only. For many patients, both approaches produce meaningful eczema clearance.

Dosing flexibility: After an initial phase, both medications are given every two weeks. A key Adbry advantage: adults under 220 lbs who achieve clear or nearly clear skin at 16 weeks may be eligible to reduce to injections every 4 weeks, cutting their injection frequency roughly in half. Dupixent does not offer this step-down option for eczema.

Age eligibility: Dupixent is FDA-approved for patients as young as 6 months old. Adbry is approved for patients ages 12 and older. If you need a biologic for a young child, Dupixent is likely the more appropriate option.

Eye side effects: Both medications can cause conjunctivitis (pink eye). Some patients who experience significant eye-related side effects on Dupixent have been successfully switched to Adbry, as the two drugs affect the eye differently. Your Honeydew provider can advise on this based on your history.

Other conditions: Dupixent is approved for multiple conditions including asthma, nasal polyps, and food allergy in addition to eczema. Adbry is currently approved only for atopic dermatitis. If you have co-occurring conditions that Dupixent also treats, that may factor into your provider's recommendation.

Since Honeydew prescribes both medications, your dermatologist can review your full history, current treatments, and insurance coverage to recommend which biologic is the better fit for you.

‍

Adbry's list price makes it sound out of reach at first glance, but most patients pay significantly less, and many pay $0. Here's how the savings programs break down:

With commercial insurance: Eligible patients can enroll in the Adbry Copay Program, which can reduce your out-of-pocket cost to as little as $0 per prescription, with up to $13,000 in annual savings. If your insurance doesn't yet cover Adbry, the Adbry Bridge Care Program can provide up to six months of free medication while your coverage is being processed — giving you access to treatment without waiting for approval to finalize.

First dose fast: If you have commercial insurance, the Adbry Rapid Access Program may allow you to receive your first dose for free within 48 hours of being prescribed, even before insurance approval is complete.

Without insurance: If you have financial need and limited or no prescription coverage, the Adbry Patient Assistance Program from LEO Pharma may provide the medication at no cost for qualifying patients.

Honeydew's membership fee (starting at $25/month on an annual plan) is separate from medication costs and is HSA/FSA eligible. We handle insurance verification, prior authorization, and specialty pharmacy coordination on your behalf — so you're never navigating the cost process alone.

Adbry may be appropriate for people with moderate to severe eczema that isn’t well controlled with topical treatments. Your provider will determine eligibility.

Adbry is given as a subcutaneous injection, typically every other week after starter doses, based on your treatment plan.

Adbry is usually used long term to maintain eczema control. Treatment duration depends on response and provider guidance.

Common side effects include injection-site reactions and eye irritation. Your provider monitors safety throughout treatment.

No. Adbry does not require pregnancy testing or special enrollment programs. Your provider will review safe use based on your medical history.

If you or your child is under the age of 18, a parent or guardian should be part of the initial consultation. In circumstances where this is not possible, please contact info@honeydewcare.com and we will assist you with alternate ways to establish parental consent.

We will run the prescriptions through your insurance and help you find the lowest costs out there. The membership fee and any products are also eligible for HSA or FSA reimbursement.

We offer comprehensive support for our patients, including access to experienced providers, assistance with lab orders and the iPledge program (when needed), unlimited support, and progress tracking.